Addressing Unmet Need: Could Children With Low-Grade Gliomas Have a New Treatment in Tovorafenib?

For Brain Cancer Awareness Month, AJMC shares an interview with Day One Biopharmaceuticals CEO Jeremy Bender, PhD, MBA. Bender discussed the company's lead agent, tovorafenib, which has shown promise in treatment of pediatric low-grade glioma.

Related Keywords

United States ,American ,Jeremy Bender ,Society For Neuro ,American Society Of Clinical Oncology ,American Society Of Pediatric Oncology Hematology Conference ,Oncology Research Conference ,Day One Biopharmaceuticals ,Day One ,Response Assessment ,Rare Pediatric Disease ,American Journal ,Managed Care ,Jude Children ,Brain Cancer Awareness Month ,Day One Bio ,American Society ,Hematology Conference ,Clinical Oncology Annual ,New Drug Application ,Accessed May ,Clinical Oncology ,Published April ,Gonazles Del Pino ,Brain Tumors ,Gliomas ,Low Grade Gliomas ,Tovorafenib ,